In the compelling follow-up to the internationally award-winning documentary, Burzynski, the Movie; Burzynski: Cancer is Serious Business, Part II explores the current status of Antineoplastons’ clinical testing sanctioned by the United States Food & Drug Administration—and features a modern story of the struggling journeys of cancer patients being treated today at the Burzynski Clinic in Houston, Texas.
For most patients undergoing Burzynski’s treatment, their advanced cancer itself runs secondary to the constant barrage of skepticism coming not only from their local oncologists, but also from friends and family who feel their loved ones are making suspect treatment decisions—even though mainstream oncology has already left many for dead.
As the story unfolds, you will observe a real-time change of hearts and minds from many of these doctors and families. Unlike the first documentary, Part II showcases interviews with board-certified oncologists, surgeons and neurosurgeons, who witnessed patients leave their care, soon to return in great health after opting for the Burzynski Clinic.
Since the mapping of the Cancer Genome, Burzynski has pioneered an expansion of his therapy which he calls, “Personalized Gene-Targeted Cancer Therapy”, where each patient’s Genomic Cancer Atlas is mapped and a treatment regimen is personally tailored for each individual patient—vs. the conveyor belt, “one-size-fits-all” approach that current oncology adheres to.
Due to the slow-moving, bureaucratic obstacles enforced on Antineoplastons by America’s FDA, this new expanded “personalized gene-targeted” direction has allowed more patients (who are denied access to Antineoplastons) to benefit from Burzynski’s practice in ways never before thought possible. And yet, still with similar resistance and controversy endured by Burzynski’s Antineoplaston therapy.
The film also takes you to Kurume University in Fukuoka, Japan—where independently designed studies of Antineoplastons have been underway for 27 years—without Dr. Burzynski’s (the inventor’s) involvement or supervision. Learn how this team of Japanese pathologists, oncologists and surgeons have studied these anti-cancer co mpounds using their own methodologies—resulting in the first ever independently-run randomized controlled clinical trials.
“After twenty-seven years of independently testing Antineoplastons—including randomized clinical trials, we found that Dr. Burzynski was right. It’s obviously not anecdotal anymore.” – Hideaki Tsuda, MD – 2013, Kurume Medical University, Fukuoka Prefecture, Japan
You will be placed into the turbulent journey of how the industry utilizes its now usurped regulatory agency to both block Antineoplastons’ Phase 3 clinical trial process—and orchestrate a group of “information hit men” (also known as an “Astroturf Campaign”) to pollute all channels of public information in an effort to confuse the public over the truth behind Antineoplastons. This international Astroturf group also engages in the intimidation and harassment of prospective and current terminal cancer patients under Dr. Burzynski’s care.
However, most notable of all—are the earth-shattering events that occurred upon the final days of production of this film—you’ll be left speechless, yet with so much to say, when you witness the story and shocking conclusion to Burzynski: Cancer Is Serious Business, Part II.
“I can’t imagine a world where other people will not have the privilege that I have had—the privilege to have their life saved by a new technology that can cure cancer—it’s terrifying.”
– Laura Hymas – 2013, Glioblastoma Grade IV brain cancer patient, after experiencing a complete remission under Antineoplaston therapy.
- Baking Soda – The Nightmare of the Pharmaceutical Industry : Body, Mind, Soul & Spirit – UPDATED DAILY! | BodyMindSoulSpirit.com
- 5G Wireless Radiation Dangers
- How Big Oil Conquered the World
- CDC Admits 98 Million Americans Were Given Cancer Virus via the Polio Shot | Humans Are Free
- Each Body Part Is In The Palm Of Your Hand-Press These Points For Wherever You Have Pain